Last reviewed · How we verify

DHA-PQP coadministered with PQ

Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · Phase 3 active Small molecule

DHA-PQP (dihydroartemisinin-piperaquine) combined with primaquine works by killing malaria parasites at multiple lifecycle stages, with DHA-PQP targeting blood-stage parasites and primaquine targeting liver-stage and gametocyte forms.

DHA-PQP (dihydroartemisinin-piperaquine) combined with primaquine works by killing malaria parasites at multiple lifecycle stages, with DHA-PQP targeting blood-stage parasites and primaquine targeting liver-stage and gametocyte forms. Used for Malaria caused by Plasmodium vivax (including relapsing malaria), Malaria caused by Plasmodium ovale, Uncomplicated malaria in endemic regions.

At a glance

Generic nameDHA-PQP coadministered with PQ
Also known asExperimental treatment with potential synergy
SponsorFundação de Medicina Tropical Dr. Heitor Vieira Dourado
Drug classArtemisinin-based combination therapy (ACT) with 8-aminoquinoline
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Dihydroartemisinin-piperaquine is a fixed-dose artemisinin-based combination therapy that rapidly eliminates asexual blood-stage Plasmodium parasites. Primaquine is added to target hypnozoites in the liver (preventing relapse in P. vivax and P. ovale) and to eliminate gametocytes (blocking transmission). This combination addresses both clinical cure and transmission reduction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: